A Day in the Life of an Oncology Clinician
The Breast Cancer Experience
Director, Triple-Negative Breast Cancer Research
Susan F. Smith Center for Women’s Cancers
Department of Medical Oncology, Dana-Farber Cancer Institute
Boston, Massachusetts
Stamford Health
Stamford, Connecticut
Target Audience
The educational design of this activity addresses the needs of oncology clinicians (physicians, nurse practitioners, physician associates, and nurses) managing patients with breast cancer.
Program Overview
Oncology clinicians face a set of complex factors when treating patients with metastatic breast cancer (mBC) using antibody-drug conjugates (ADCs), from navigating emerging clinical trial data, to choosing appropriate ADCs for their patients' individual needs, to managing adverse events that may occur during or following treatment. Join Dr. Ana Garrido-Castro;as she guides learners through the "A Day in the Life of an Oncology Clinician: The Breast Cancer Experience" program and helps unravel some of the complexity surrounding ADC use in mBC. Using a unique digital format that combines physician-patient interactions with exciting didactic content and features a peer consult with Dr. Kelsey Sokol, learners will be immersed in the current treatment landscape for ADCs in mBC and have the opportunity to follow along with Dr. Garrido-Castro as she engages in clinical decision-making scenarios that may reflect what they see in daily practice.
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the clinical profiles of currently available ADC therapy developed to treat advanced/metastatic BC
- Discuss the latest clinical trial data on currently available and emerging ADC monotherapy and combination therapies for patients with advanced/metastatic BC
- Individualize treatment with ADC therapy for advanced/metastatic BC based on patient and disease characteristics, treatment history, and biomarker testing
- Implement strategies to mitigate and manage potential treatment-emergent adverse events associated with ADC therapy
Physician Accreditation Statement
Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ANCC Reciprocity Statement
The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.
Integritas Contact Information
For more information about the approval of this program, please contact Integritas at info@exchangecme.com.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Preactivity Questions.
- Review the activity content.
- Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Conflicts of Interest
Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Ana C. Garrido-Castro, MD: Consulting Fees: AstraZeneca, Bicycle Therapeutics, BioNTech, Bristol-Myers Squibb Company, Daiichi Sankyo, Gilead Sciences, Merck & Co., Novartis Pharmaceuticals Corporation, Pfizer, Roche/Genentech, TD Cowen; Contracted Research: AstraZeneca, Bicycle Therapeutics, BioNTech, Biovica International, Bristol-Myers Squibb Company, Case45, Daiichi Sankyo, Foundation Medicine, Gilead Sciences, Merck & Co., Novartis Pharmaceuticals Corporation, Precede Biosciences, Reveal Genomics, Zenith Epigenetics, 4D Path; Steering Committees: AstraZeneca, Daiichi Sankyo, Merck & Co.
Kelsey Sokol, MD: Nothing to disclose
The planners and managers have no relevant financial relationships with ineligible companies.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is provided by Integritas Communications.
This activity is supported by an educational grant from Gilead Science, Inc.
